Format

Send to

Choose Destination
Expert Rev Pharmacoecon Outcomes Res. 2005 Dec;5(6):659-60. doi: 10.1586/14737167.5.6.659.

Are USA payers moving beyond pharmaceutical budget impact models and embracing cost-effectiveness analysis?

PMID:
19807605
DOI:
10.1586/14737167.5.6.659

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center